←
Maria J. Ribal15,742 posts
Maria J. Ribal avatar✓

Maria J. Ribal ✓

@MariaJRibal

Head of Uro-Oncology Unit. @hospitalclinic. Chair of #eauguidelines Office uroweb.org/guidelines In love with Urology!! Passion for life!!!

◷ Joined May 2014▧ 879 Photos and videos
Mirrors of Medicine avatar
⟳ Maria J. Ribal retweeted
Mirrors of Medicine@mirrorsmed·Nov 13

🌍 73 UTUC experts. 40 clinical questions. 80% consensus. What should standard practice look like in non-metastatic UTUC? nature.com/articles/s41585-0… International multidisciplinary Delphi consensus on advanced practice in non-metastatic upper tract urothelial carcinoma (IMPACT UTUC) The IMPACT UTUC international Delphi consensus provides expert guidance for non-metastatic upper tract urothelial carcinoma (UTUC), addressing persistent variability in diagnosis, staging, and treatment. ➡️ Seventy-three multidisciplinary experts from Europe, the Americas, and Asia evaluated 40 statements across two rounds. Consensus was reached for 32 statements (80%). ➡️ These recommendations offer a practical, internationally informed framework for current clinical practice and identify areas where prospective evidence remains urgently needed. #BladderCancer @PandolfoSD, @RobertoContieri, @pcvblack, @uretericbud, @danieleamparore, @aleantonellibs1, @RicBertolo, @AlbertoBreda1, @agallioli, @Albert0Briganti, @UroMoschini, @saumyg, @GuidoGiusti, @paolo_gontero, @gonzomdphd, @PGrivasMDPhD, @UroDocAsh, @UrogerliMD, @Dr_Jen_Linehan, @ParamMariappan, @MehrazinMD, @LAUrology_NL, @minerviniandre, @andreamari08, @AndreaNecchi, @montypal , @JamesPorterMD, @BenjaminPradere, @spsutkaMD, @urojdr, @MRoupret, @DrShariat, @nirmishsingla, @endouro, @sonpavde, @cnsternberg, @mdstifelman, @jteoh_hk, @homizargar, @rebeccampbell50, @MariaJRibal, @LiMingSu1, @shilpaonc, @LauraBukavinaMD, @Hoomandjaladat, @Cold_Steel_1970, @ricautor, @Ric_Campi

Post attachment
Hospital Clínic avatar
⟳ Maria J. Ribal retweeted
Hospital Clínic@hospitalclinic·Nov 12

🎯 Per primera vegada, el #CLÍNIC ha tractat un tumor renal amb una sola sessió de radioteràpia d'alta precisió. 🩺 L'equip d'Oncologia Radioteràpica, integrat al Clínic Barcelona Comprehensive Cancer Centre (4CB), ha aplicat aquesta tècnica, la SBRT, a un pacient amb càncer de ronyó que no podia operar-se. 🏥 És un tractament no invasiu i ambulatori, i es va fer a la seu de Granollers, a prop de casa del pacient. 👉 f.mtr.cool/8a0o0a7j54 #4CB #CàncerDeRonyó #Radioteràpia

Post attachment
NEJM avatar
⟳ Maria J. Ribal retweeted
NEJM@NEJM·Oct 24

Presented at #ESMO26: In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm @myESMO

Post attachment
Tom Powles avatar
⟳ Maria J. Ribal retweeted
Tom Powles@tompowles1·Oct 24

VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.

Post attachmentPost attachmentPost attachmentPost attachment
Tom Powles avatar
⟳ Maria J. Ribal retweeted
Tom Powles@tompowles1·Oct 24

ctDNA analysis is an increasingly utilised prognostic tool in muscle invasive bladder cancer. In VOLGA 78% of the muscle invasive bladder cancer patients were ctDNA positive at baseline which was prognostic. Also, the combination of perioperative durvalumab and neoadjuvant EV cleared ctDNA in 60% of patients (using the Natera Genome assay which has increased sensitivity). Clearance was associated with much better outcomes. #ESMO26

Post attachment
Tom Powles avatar
⟳ Maria J. Ribal retweeted
Tom Powles@tompowles1·Oct 24

VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment